"Neoplasm, Residual" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Remnant of a tumor or cancer after primary, potentially curative therapy.
| Descriptor ID |
D018365
|
| MeSH Number(s) |
C04.697.700 C23.550.727.700
|
| Concept/Terms |
Neoplasm, Residual- Neoplasm, Residual
- Residual Neoplasms
- Residual Neoplasm
- Minimal Residual Disease
- Minimal Disease, Residual
- Residual Minimal Disease
- Residual Minimal Diseases
- Residual Disease, Minimal
- Minimal Residual Diseases
Residual Tumor- Residual Tumor
- Residual Tumors
- Residual Tumour
- Residual Tumours
- Tumour, Residual
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm, Residual".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm, Residual".
This graph shows the total number of publications written about "Neoplasm, Residual" by people in this website by year, and whether "Neoplasm, Residual" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 3 | 3 |
| 2002 | 0 | 2 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 2 | 3 |
| 2009 | 1 | 4 | 5 |
| 2010 | 2 | 2 | 4 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 4 | 5 |
| 2013 | 0 | 2 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 3 | 4 |
| 2016 | 0 | 5 | 5 |
| 2017 | 1 | 4 | 5 |
| 2018 | 1 | 3 | 4 |
| 2019 | 3 | 2 | 5 |
| 2020 | 1 | 4 | 5 |
| 2021 | 1 | 7 | 8 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 1 | 3 |
| 2025 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.
-
Current options and future perspectives for margin assessment in breast conservation surgery. Eur J Surg Oncol. 2025 Sep; 51(9):110215.
-
Navigating B-ALL in the Era of Blinatumomab. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e472778.
-
Radiation Therapy Dose Escalation Failed to Improve Local Control for Intermediate-Risk Rhabdomyosarcoma on ARST1431: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2025 Sep 01; 123(1):54-62.
-
Predictors of residual neoplasia after noncurative (R1) endoscopic submucosal dissection of lesions in the gastrointestinal tract. Eur J Gastroenterol Hepatol. 2024 Oct 01; 36(10):1180-1185.
-
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 05 16; 143(20):2053-2058.
-
Characterization of residual cancer by comparison of a pair of organoids established from a patient with esophageal squamous cell carcinoma before and after neoadjuvant chemotherapy. Hum Cell. 2024 Mar; 37(2):491-501.
-
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078.
-
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2024 Jan 10; 42(2):218-227.
-
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol. 2023 10; 34(10):899-906.
-
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023 Jul; 10(7):e510-e520.